Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection

Significance More than 50 years ago, Epstein–Barr virus (EBV) was found to infect resting human B lymphocytes and to induce their continuous proliferation in vitro. This seminal finding clearly mimics aspects of EBV’s oncogenic potential in vivo but how EBV activates primary human B lymphocytes and how lymphoblastoid cell lines (LCLs) evolve from the EBV-infected lymphocytes is uncertain. We studied this model and found that the EBV-infected naïve B lymphocytes undergo a germinal center-like activation and differentiation program within only a few days after infection to emerge with transcriptomic and phenotypic features resembling plasmablasts and early plasma cells. In vitro in established LCLs, EBV “locks” the infected B cells in a stage of differentiation that is only transient in vivo. Epstein–Barr virus (EBV) is a human tumor virus and a model of herpesviral latency. The virus efficiently infects resting human B lymphocytes and induces their continuous proliferation in vitro, which mimics certain aspects of EBV’s oncogenic potential in vivo. How lymphoblastoid cell lines (LCLs) evolve from the infected lymphocytes is uncertain. We conducted a systematic time-resolved longitudinal study of cellular functions and transcriptional profiles of newly infected naïve primary B lymphocytes. EBV reprograms the cells comprehensively and globally. Rapid and extensive transcriptional changes occur within 24 h and precede any metabolic and phenotypic changes. Within 72 h, the virus activates the cells, changes their phenotypes with respect to cell size, RNA, and protein content, and induces metabolic pathways to cope with the increased demand for energy, supporting an efficient cell cycle entry on day 3 postinfection. The transcriptional program that EBV initiates consists of 3 waves of clearly discernable clusters of cellular genes that peak on day 2, 3, or 4 and regulate RNA synthesis, metabolic pathways, and cell division, respectively. Upon onset of cell doublings on day 4, the cellular transcriptome appears to be completely reprogrammed to support the proliferating cells, but 3 additional clusters of EBV-regulated genes fine-tune cell signaling, migration, and immune response pathways, eventually. Our study reveals that more than 11,000 genes are regulated upon EBV infection as naïve B cells exit quiescence to enter a germinal center-like differentiation program, which culminates in immortalized, proliferating cells that partially resemble plasmablasts and early plasma cells.

[1]  W. Hammerschmidt,et al.  The first days in the life of naïve human B-lymphocytes infected with Epstein-Barr virus , 2019, bioRxiv.

[2]  Mingxiang Teng,et al.  RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes , 2019, Journal of Virology.

[3]  E. Kashuba,et al.  Expression of the chemokine receptors CCR1 and CCR2B is up-regulated in peripheral blood B cells upon EBV infection and in established lymphoblastoid cell lines. , 2017, Virology.

[4]  G. Kelly,et al.  EBV and Apoptosis: The Viral Master Regulator of Cell Fate? , 2017, Viruses.

[5]  A. Rickinson,et al.  Epstein–Barr virus-associated lymphomas , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.

[6]  W. Hammerschmidt,et al.  MicroRNAs of Epstein-Barr Virus Control Innate and Adaptive Antiviral Immunity , 2017, Journal of Virology.

[7]  William Stafford Noble,et al.  Integrated systems biology analysis of KSHV latent infection reveals viral induction and reliance on peroxisome mediated lipid metabolism , 2017, PLoS pathogens.

[8]  E. Kieff,et al.  Epstein–Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation , 2016, Proceedings of the National Academy of Sciences.

[9]  T. Sparwasser,et al.  Metabolic pathways in T cell activation and lineage differentiation. , 2016, Seminars in immunology.

[10]  L. Young,et al.  Epstein–Barr virus: more than 50 years old and still providing surprises , 2016, Nature Reviews Cancer.

[11]  Kyoung-Jae Won,et al.  EBNA2 Drives Formation of New Chromosome Binding Sites and Target Genes for B-Cell Master Regulatory Transcription Factors RBP-jκ and EBF1 , 2016, PLoS pathogens.

[12]  Ruoning Wang,et al.  T cell metabolic reprogramming and plasticity. , 2015, Molecular immunology.

[13]  C. Dang,et al.  MYC, Metabolism, and Cancer. , 2015, Cancer discovery.

[14]  M. Buck,et al.  T cell metabolism drives immunity , 2015, The Journal of experimental medicine.

[15]  W. Hammerschmidt,et al.  K1 and K15 of Kaposi's Sarcoma-Associated Herpesvirus Are Partial Functional Homologues of Latent Membrane Protein 2A of Epstein-Barr Virus , 2015, Journal of Virology.

[16]  Thierry Fest,et al.  GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells , 2015, PLoS Comput. Biol..

[17]  A. Kieser,et al.  The Latent Membrane Protein 1 (LMP1). , 2015, Current topics in microbiology and immunology.

[18]  E. Pearce,et al.  SnapShot: Immunometabolism. , 2015, Cell metabolism.

[19]  Hanspeter Pfister,et al.  UpSet: Visualization of Intersecting Sets , 2014, IEEE Transactions on Visualization and Computer Graphics.

[20]  J. Rathmell,et al.  Metabolic Reprogramming towards Aerobic Glycolysis Correlates with Greater Proliferative Ability and Resistance to Metabolic Inhibition in CD8 versus CD4 T Cells , 2014, PloS one.

[21]  M. Luftig,et al.  Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. , 2014, Advances in virus research.

[22]  Amy M. Holthaus,et al.  Epstein–Barr Virus Nuclear Antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A , 2013, Proceedings of the National Academy of Sciences.

[23]  W. Hammerschmidt,et al.  Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation. , 2013, Current opinion in virology.

[24]  D. Green,et al.  Metabolic checkpoints in activated T cells , 2012, Nature Immunology.

[25]  S. Dave,et al.  Analysis of Epstein-Barr Virus-Regulated Host Gene Expression Changes through Primary B-Cell Outgrowth Reveals Delayed Kinetics of Latent Membrane Protein 1-Mediated NF-κB Activation , 2012, Journal of Virology.

[26]  W. Hammerschmidt,et al.  The EBV Immunoevasins vIL-10 and BNLF2a Protect Newly Infected B Cells from Immune Recognition and Elimination , 2012, PLoS pathogens.

[27]  W. Hammerschmidt,et al.  RNAs in Epstein–Barr virions control early steps of infection , 2012, Proceedings of the National Academy of Sciences.

[28]  W. Hammerschmidt,et al.  Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus. , 2012, European journal of cell biology.

[29]  J. Rathmell T cell Myc-tabolism. , 2011, Immunity.

[30]  D. Green,et al.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.

[31]  W. Hammerschmidt,et al.  The Lytic Phase of Epstein-Barr Virus Requires a Viral Genome with 5-Methylcytosine Residues in CpG Sites , 2011, Journal of Virology.

[32]  John Quackenbush,et al.  Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth , 2011, Proceedings of the National Academy of Sciences.

[33]  Mario Roederer,et al.  Interpretation of cellular proliferation data: Avoid the panglossian , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[34]  Robert E. White,et al.  An ATM/Chk2-mediated DNA damage responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells , 2010, Cell host & microbe.

[35]  W. Hammerschmidt,et al.  AP-1 homolog BZLF1 of Epstein–Barr virus has two essential functions dependent on the epigenetic state of the viral genome , 2009, Proceedings of the National Academy of Sciences.

[36]  M. Jourdan,et al.  An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. , 2009, Blood.

[37]  G. Klein,et al.  Changes in chemokines and chemokine receptor expression on tonsillar B cells upon Epstein–Barr virus infection , 2009, Immunology.

[38]  R. Scarpulla Transcriptional paradigms in mammalian mitochondrial biogenesis and function. , 2008, Physiological reviews.

[39]  Jonghwan Kim,et al.  Global Identification of Myc Target Genes Reveals Its Direct Role in Mitochondrial Biogenesis and Its E-Box Usage In Vivo , 2008, PloS one.

[40]  B. Sugden,et al.  The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis. , 2008, Blood.

[41]  Erik Flemington,et al.  B-cell Receptor Activation Induces BIC/miR-155 Expression through a Conserved AP-1 Element* , 2008, Journal of Biological Chemistry.

[42]  W. Hammerschmidt,et al.  Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. , 2007, Blood.

[43]  Maria R. Gumina,et al.  Cutting Edge: IL-4-Mediated Protection of Primary B Lymphocytes from Apoptosis via Stat6-Dependent Regulation of Glycolytic Metabolism1 , 2007, The Journal of Immunology.

[44]  M. Ressing,et al.  A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates , 2007, The Journal of experimental medicine.

[45]  T. Kanda,et al.  Epstein-Barr Virus BZLF1 Gene, a Switch from Latency to Lytic Infection, Is Expressed as an Immediate-Early Gene after Primary Infection of B Lymphocytes , 2006, Journal of Virology.

[46]  T. Chiles,et al.  Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. , 2006, Blood.

[47]  W. Hammerschmidt,et al.  Epstein-Barr Virus Provides a New Paradigm: A Requirement for the Immediate Inhibition of Apoptosis , 2005, PLoS biology.

[48]  L. Young,et al.  Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.

[49]  Stephen P. Schoenberger,et al.  Dynamic programming of CD8+ T lymphocyte responses , 2003, Nature Immunology.

[50]  K. Takada,et al.  Human B Cells Immortalized with Epstein-Barr Virus Upregulate CCR6 and CCR10 and Downregulate CXCR4 and CXCR5 , 2002, Journal of Virology.

[51]  B. Kempkes,et al.  The Proto-Oncogene c-myc Is a Direct Target Gene of Epstein-Barr Virus Nuclear Antigen 2 , 1999, Journal of Virology.

[52]  W. Hammerschmidt,et al.  Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  L. Strobl,et al.  Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notch1 transactivate genes by interacting with the cellular protein RBP-J kappa. , 1997, Immunobiology.

[54]  R. Tampé,et al.  Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10 , 1997 .

[55]  R. Tampé,et al.  Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. , 1997, Blood.

[56]  W. Henle Evidence for viruses in acute leukemia and Burkitt's tumor , 1968, Cancer.

[57]  J. H. Pope Establishment of Cell Lines from Peripheral Leucocytes in Infectious Mononucleosis , 1967, Nature.

[58]  M. Epstein,et al.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.

[59]  R. Pulvertaft,et al.  CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). , 1964, Lancet.